Evidence map›Paper›PMID 41446220›Full record

ArticlebioRxiv : the preprint server for biology2025

CyTOF-based profiling of circulating tumor cells predicts aggressiveness and therapy response in SCLC liquid biopsies at a personalized level.

Mukulika Bose, Cole Ruoff, Shafqat Ehsan, C Allison Stewart, Alberto Duarte, Sayantan Bhattacharyya, Jiaqi Li, Anchang Benedict, Thomas Welte, Ashley Victorian and 12 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Mukulika BoseDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Texas 77030.ORCID 0000-0002-2347-7413
Cole RuoffDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Texas 77030.
Shafqat EhsanDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Texas 77030.
C Allison StewartDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas 77030.ORCID 0000-0002-7758-1179
Alberto DuarteDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas 77030.
Sayantan BhattacharyyaDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Texas 77030.
Jiaqi LiBiostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, 111 T W Alexander Dr Rall Building, Research Triangle Park, 27709, Durham, NC, United States.
Anchang BenedictBiostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, 111 T W Alexander Dr Rall Building, Research Triangle Park, 27709, Durham, NC, United States.
Thomas WelteDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Texas 77030.
Ashley VictorianDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Texas 77030.
Fabiola E LujanDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Texas 77030.
Lixia DiaoDepartment of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Texas 77030.
Jing WangDepartment of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Texas 77030.
Ken ChenDepartment of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Texas 77030.ORCID 0000-0003-4013-5279
Bingnan ZhangDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas 77030.
Runsheng WangDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas 77030.
Luisa Solis SotoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Texas 77030.
Alejandra G SerranoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Texas 77030.
Robert CardnellDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas 77030.
Carl M GayDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas 77030.
Lauren A ByersDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas 77030.
Loukia G KaracostaDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Texas 77030.ORCID 0000-0002-1491-4773

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V. · 1996 to 2024
$57.4M
Therapeutic strategies for targeting PARP1 in small cell lung cancerR01CA207295 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Lauren Averett Byers · 2016 to 2026
$3.7M
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic responseU01CA256780 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BYERS, LAUREN AVERETT, HEYMACH, JOHN V. · 2021 to 2025
$3.0M
Modeling tumor heterogeneity, to develop new therapeutic strategies for treatment of resistant small cell lung cancerR50CA243698 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Catherine Allison Stewart · 2020 to 2026
$701k
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA207295NCI NIH HHS R50 CA243698NCI NIH HHS U01 CA256780
6 · The paper itself

Abstract

Small-cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma characterized by high numbers of circulating tumor cells (CTCs). We applied CyTOF and a 20-marker antibody panel to detect and phenotype CTCs directly in liquid biopsies of 51 SCLC patients (treatment-naïve, chemotherapy and immunotherapy-treated, and tarlatamab-treated), of which a subset were longitudinally tracked. Unsupervised clustering revealed distinct cell populations enriched in patient liquid biopsies compared to those from healthy donors. Further analysis identified CTC populations of the three established SCLC subtypes driven by the high expression of ASCL1, NeuroD1, and POU2F3 transcription factors respectively. Significant differences in CTC EMT markers, established therapeutic targets (e.g. DLL3), and subtype heterogeneity were observed between naïve versus treated samples. Changes in subtype proportions were observed in longitudinally tracked samples in both treatment modalities. Our study demonstrates the utility of CyTOF for high-resolution CTC profiling, offering dynamic insights into CTC heterogeneity, treatment response, and resistance mechanisms.

Indexed as

BiomarkersCirculating Tumor CellsCyTOFEMTLiquid biopsiesSmall Cell Lung CancerSubtyping

Identifiers

PMID41446220
PMCPMC12724418

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.